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OBJECTIVE — Serum insulin-like growth factor (IGF)-1 may have a role in the maintenance
of glucose homeostasis. We examined the association between serum IGF-1 and diabetes in a
representative sample of U.S. adults.
RESEARCH DESIGN AND METHODS — Third National Health and Nutrition Exam-
ination Survey (NHANES III) participants aged 18 years (n  5,511) were the subjects of the
study. The main outcome was the presence of diabetes (n  387).
RESULTS — Lower serum IGF-1 levels were positively associated with diabetes after adjust-
ing for age, sex, race/ethnicity, education, smoking, alcohol intake, BMI, hypertension, glomer-
ularﬁltrationrate,andserumcholesterol.Comparedwithquartile4ofIGF-1(referent),theodds
ratio (OR) of diabetes associated with quartile 1 was OR 2.16 (95% CI 1.24–3.76); P-trend 
0.002.However,theobservedassociationbetweenIGF-1anddiabeteswaspresentonlyinthose
65 years of age (OR  3.05; P-trend  0.006) and disappeared in those 65 years of age
(OR  0.51; P-trend  0.18); P-interaction  0.0056.
CONCLUSIONS — Low IGF-1 levels are associated with diabetes among young subjects.
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I
nsulin-like growth factor (IGF)-1 is in-
volved in the regulation of growth and
cellular proliferation in the human
body(1,2).IGF-1issimilarinstructureto
insulin. Reduced IGF-1 levels have been
proposed to have a role in diabetes (3–5).
The two previous studies on IGF-1 and
diabetes were restricted to elderly popu-
lations (6) or had limited sample size (7).
There also is some inconsistency in the
ﬁndings of the two studies: one study (7)
found a positive association with decreas-
ing IGF-1, while the other study (6) did
not ﬁnd an association. Therefore, this
study examined the independent associa-
tion between IGF-1 and diabetes in a rep-
resentative sample of U.S. adults.
RESEARCH DESIGN AND
METHODS— We used data from the
Third National Health and Nutrition Ex-
amination Survey (NHANES III) (8–11),
which included a probability sample of
the U.S. population. We examined sub-
jects 18 years of age randomly assigned
to the morning exam after an overnight
fast. Serum IGF-1 was measured in 6,059
participants. Subjects were excluded that
had cardiovascular disease (n  400) and
missing data (n  148) on covariates in-
cluded in the multivariable model. This
resulted in 5,511 participants, 387 of
whom had diabetes.
Diabetes was deﬁned as serum glu-
cose 126 mg/dl (if fasting 8 h), a se-
rum glucose 200 mg/dl (if fasting 8
h), history of diabetes diagnosis, or cur-
rent use of oral hypoglycemics or insulin.
IGF-1 measurement has been previously
described (10).
We hypothesized that low IGF-1 lev-
els are associated with diabetes. The odds
ratio (OR) of diabetes for IGF-1 was cal-
culated by taking the highest IGF-1 quar-
tile as the referent using multivariable
logistic regression models. Sample
weights for the complex survey design
were applied for all analyses using SAS
and SUDAAN software.
RESULTS— Decreasing levels of
IGF-1 were positively associated with di-
abetes in the multivariable-adjusted
model (Table 1). In a subgroup analysis
by age, decreasing levels of serum IGF-1
were positively associated with diabetes
in those aged 65 years (P-trend 
0.008); the association disappeared in
those aged 65 years (P-trend  0.19).
In a supplementary analysis to exam-
ine if the association between IGF-1 and
diabetes was explained by inﬂammation,
we additionally adjusted for high-
sensitivity C-reactive protein levels. The
results were unaltered. In a second sup-
plementary analysis, we examined the
IGF-1 and diabetes association after addi-
tionally adjusting for IGF binding protein
(IGFBP)-3levels.Comparedwithquartile
4 (referent) of IGF-1, the OR of diabetes
was 1.57 (95% CI 0.81–3.02) for quar-
tile 3; 2.79 (1.68–4.63) for quartile 2;
and 3.83 (1.98–7.39) for quartile 1;
P-trend 0.0001.Inathirdsupplemen-
tary analysis, we examined the indepen-
dent association between IGFBP-3 and
diabetesafteradjustingforvariablesinthe
multivariable model and, additionally,
IGF-1 levels. Compared with quartile 1
(referent) of IGFBP-3, the OR of diabetes
was 0.85 (0.54–1.36) for quartile 2; 1.08
(0.51–2.30) for quartile 3; and 2.50
(1.27–4.93) for quartile 4; P-trend 
0.01. In a fourth supplementary analysis,
we examined the IGF-diabetes associa-
tion by sex. Decreasing levels of serum
IGF-1 were associated with diabetes in
both men and women; P-interaction for
cross-product sex  IGF-1 term 
0.3431.Inaﬁnalsupplementaryanalysis,
we examined the IGF-diabetes associa-
tion according to the two main categories
of diabetes deﬁnition: past history/self-
reported diabetes and elevated fasting
glucose. For self-reported diabetes, com-
pared with quartile 4 (referent) of IGF-1,
the OR of self-reported diabetes was 1.43
(0.46–4.44) for quartile 3; 1.29 (0.50–
3.31)forquartile2;and3.28(1.11–9.66)
for quartile 1; P-trend  0.06. For diabe-
tes deﬁned based on blood glucose levels,
compared with quartile 4 (referent) of
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(0.79–4.36) for quartile 3; 3.77 (1.83–
7.76) for quartile 2; and 5.59 (2.09–
15.00) for quartile 4; P-trend  0.0001.
CONCLUSIONS — In a representa-
tive sample of U.S. adults without clinical
cardiovascular disease, we found low lev-
els of serum IGF-1 to be positively asso-
ciated with diabetes. When we examined
the association between serum IGF-1 and
diabetes by age, low serum IGF-1 was
positivelyassociatedwithdiabetesonlyin
subjects65yearsofageandnotinthose
65 years of age. Our results contribute
to the existing literature (6,7) by suggest-
ing that low IGF-1 may be a predictor of
diabetes only in younger subjects. How-
ever, the cross-sectional nature of our
study precludes conclusions regarding
the temporal nature of the association be-
tween IGF-1 and diabetes.
Sandhu et al. (7) reported a positive
association between low IGF-1 levels and
glucose intolerance/diabetes in a sample
of 615 subjects 45–65 years of age. In
contrast, Rajpatak et al. (6) recently did
not ﬁnd an independent association be-
tween IGF-1 and diabetes among 922
subjects 65 years of age from the Car-
diovascular Health Study. It has been
shown that growth hormone and IGF-1
levels decline with age. Therefore, if
IGF-1 has an independent role in glu-
cose homeostasis, it is possible that this
effect is less pronounced in older
individuals.
In the current study, we had an ade-
quate sample size to examine the associa-
tion between IGF-1 and diabetes separately
among younger and older subjects. We
found that the association between low
IGF-1 and diabetes was strongly present
among subjects who were 65 years of
age, but the association disappeared in
those 65 years of age. Therefore, this
clariﬁestheseeminginconsistencyinpre-
vious literature (6,7) by suggesting that
the difference in the age groups of sub-
jects examined in those studies may be a
reason for their difference in ﬁndings.
However, the robustness of our ﬁndings
of an interaction by age in the IGF-
diabetes association should be inter-
preted with caution and needs to be
conﬁrmed in future larger studies with
follow-up data.
IGFBP-3 may inhibit the bioactivity
of IGF-1 by sequestering IGF-1 into a
circulating reservoir, thereby reducing
the free-circulating fraction of IGF-1
(12). In the current study, adjusting for
IGFBP-3 levels in the multivariable
model accentuated the association be-
tween IGF-1 and diabetes, suggesting
that the observed association is mainly
due to the effect of IGFBP-independent
free fraction of IGF-1. We also found
that IGFBP levels were positively asso-
ciated with diabetes, even after addi-
tionally adjusting for serum IGF-1
levels, suggesting that IGFBP may have
IGF-1–independent effects (13). In
conclusion, lower IGF-1 levels were
positively associated with diabetes in
younger subjects.
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